{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:07:30Z","timestamp":1788995250043,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40256-025-00723-2","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T17:15:40Z","timestamp":1741367740000},"page":"427-432","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Mineralocorticoid Receptor Antagonism with Finerenone: A New Era in the Management of Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7065-2096","authenticated-orcid":false,"given":"Panagiotis I.","family":"Georgianos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christodoula","family":"Kourtidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Kontogiorgos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilios","family":"Vaios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Leivaditis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gossios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilios","family":"Liakopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"issue":"2","key":"723_CR1","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","volume":"42","author":"R Agarwal","year":"2021","unstructured":"Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, Zannad F. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42(2):152\u201361.","journal-title":"Eur Heart J"},{"issue":"10","key":"723_CR2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709\u201317.","journal-title":"N Engl J Med"},{"issue":"14","key":"723_CR3","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"723_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"17","key":"723_CR5","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):1757\u201380.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"723_CR6","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(3):3627\u201339.","journal-title":"Eur Heart J"},{"issue":"9","key":"723_CR7","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/ejhf.1182","volume":"20","author":"G Savarese","year":"2018","unstructured":"Savarese G, Carrero JJ, Pitt B, et al. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail. 2018;20(9):1326\u201334.","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"723_CR8","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/ejhf.1199","volume":"20","author":"M Trevisan","year":"2018","unstructured":"Trevisan M, de Deco P, Xu H, et al. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. Eur J Heart Fail. 2018;20(8):1217\u201326.","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"723_CR9","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1002\/ejhf.2287","volume":"23","author":"M Trevisan","year":"2021","unstructured":"Trevisan M, Fu EL, Xu Y, et al. Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care. Eur J Heart Fail. 2021;23(10):1698\u2013707.","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"723_CR10","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jchf.2022.06.010","volume":"10","author":"JP Ferreira","year":"2022","unstructured":"Ferreira JP, Pitt B, McMurray JJV, et al. Steroidal MRA across the spectrum of renal function: a pooled analysis of RCTs. JACC Heart Fail. 2022;10(11):842\u201350.","journal-title":"JACC Heart Fail."},{"issue":"41","key":"723_CR11","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","volume":"43","author":"J Butler","year":"2022","unstructured":"Butler J, Anker SD, Lund LH, et al. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. Eur Heart J. 2022;43(41):4362\u201373.","journal-title":"Eur Heart J"},{"issue":"15","key":"723_CR12","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383\u201392.","journal-title":"N Engl J Med"},{"issue":"1","key":"723_CR13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","volume":"131","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131(1):34\u201342.","journal-title":"Circulation"},{"issue":"9","key":"723_CR14","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.ekir.2021.05.027","volume":"6","author":"PI Georgianos","year":"2021","unstructured":"Georgianos PI, Agarwal R. Mineralocorticoid receptor antagonism in chronic kidney disease. Kidney Int Rep. 2021;6(9):2281\u201391.","journal-title":"Kidney Int Rep."},{"issue":"36","key":"723_CR15","doi-asserted-by":"publisher","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","volume":"290","author":"L Amazit","year":"2015","unstructured":"Amazit L, Le Billan F, Kolkhof P, et al. Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1. J Biol Chem. 2015;290(36):21876\u201389.","journal-title":"J Biol Chem"},{"issue":"5","key":"723_CR16","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/FJC.0000000000000366","volume":"67","author":"J Grune","year":"2016","unstructured":"Grune J, Benz V, Brix S, et al. Steroidal and nonsteroidal mineralocorticoid receptor antagonists cause differential cardiac gene expression in pressure overload-induced cardiac hypertrophy. J Cardiovasc Pharmacol. 2016;67(5):402\u201311.","journal-title":"J Cardiovasc Pharmacol"},{"key":"723_CR17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.bcp.2019.07.001","volume":"168","author":"D Lavall","year":"2019","unstructured":"Lavall D, Jacobs N, Mahfoud F, Kolkhof P, Bohm M, Laufs U. The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling. Biochem Pharmacol. 2019;168:173\u201383.","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"723_CR18","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/cpdd.263","volume":"5","author":"R Heinig","year":"2016","unstructured":"Heinig R, Kimmeskamp-Kirschbaum N, Halabi A, Lentini S. Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94\u20138862) in individuals with renal impairment. Clin Pharmacol Drug Dev. 2016;5(6):488\u2013501.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"27","key":"723_CR19","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","volume":"37","author":"G Filippatos","year":"2016","unstructured":"Filippatos G, Anker SD, Bohm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease. Eur Heart J. 2016;37(27):2105\u201314.","journal-title":"Eur Heart J"},{"issue":"31","key":"723_CR20","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453\u201363.","journal-title":"Eur Heart J"},{"issue":"6","key":"723_CR21","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474\u201384.","journal-title":"Eur Heart J"},{"issue":"23","key":"723_CR22","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"issue":"24","key":"723_CR23","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252\u201363.","journal-title":"N Engl J Med"},{"issue":"6","key":"723_CR24","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/ejhf.2469","volume":"24","author":"G Filippatos","year":"2022","unstructured":"Filippatos G, Pitt B, Agarwal R, et al. Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. Eur J Heart Fail. 2022;24(6):996\u20131005.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"723_CR25","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/ejhf.3253","volume":"26","author":"M Vaduganathan","year":"2024","unstructured":"Vaduganathan M, Claggett BL, Lam CSP, et al. Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial. Eur J Heart Fail. 2024;26(6):1324\u201333.","journal-title":"Eur J Heart Fail"},{"issue":"16","key":"723_CR26","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391(16):1475\u201385.","journal-title":"N Engl J Med"},{"issue":"2","key":"723_CR27","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jacc.2024.10.091","volume":"85","author":"FR Mc Causland","year":"2025","unstructured":"Mc Causland FR, Vaduganathan M, Claggett BL, et al. Finerenone and kidney outcomes in patients with heart failure: the FINEARTS-HF trial. J Am Coll Cardiol. 2025;85(2):159\u201368.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"723_CR28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/HJH.0000000000003330","volume":"41","author":"R Agarwal","year":"2023","unstructured":"Agarwal R, Ruilope LM, Ruiz-Hurtado G, et al. Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. J Hypertens. 2023;41(2):295\u2013302.","journal-title":"J Hypertens"},{"issue":"2","key":"723_CR29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1161\/CIRCULATIONAHA.124.072055","volume":"151","author":"M Vaduganathan","year":"2025","unstructured":"Vaduganathan M, Claggett BL, Kulac IJ, et al. Effects of the non-steroidal MRA finerenone with and without concomitant SGLT2 inhibitor use in heart failure. Circulation. 2025;151(2):149\u201358.","journal-title":"Circulation"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00723-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-025-00723-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00723-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T07:08:22Z","timestamp":1751699302000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-025-00723-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["723"],"URL":"https:\/\/doi.org\/10.1007\/s40256-025-00723-2","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]},"assertion":[{"value":"10 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by HEAL-Link Greece. This work was not supported by any source and represents an original effort of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no conflict of interest relevant to this work to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Writing original draft preparation: P.I.G., C.K., and I.K. Writing review and editing: V.V., K.L., T.G., and V.L. Supervision: V.L. All authors read and agreed to the published version of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"No datasets were generated or analyzed during the current study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}